Co-occurrence of ARID1A alterations with PI3K/AKT pathway activation has been reported in ovarian clear cell carcinoma, breast cancer, and gastric cancer (Huang et al., 2014; Samartzis et al., 2014; Zhang et al., 2016; De & Dey, 2019). This evidence concerns the gene ARID1A and ovarian clear cell cancer.